TSHA logo

Taysha Gene Therapies, Inc. (TSHA) Cash From Financing

Annual CFF:

$76.68M-$59.71M(-43.78%)
December 31, 2024

Summary

  • As of today, TSHA annual cash from financing is $76.68 million, with the most recent change of -$59.71 million (-43.78%) on December 31, 2024.
  • During the last 3 years, TSHA annual cash from financing has risen by +$37.60 million (+96.21%).
  • TSHA annual cash from financing is now -73.65% below its all-time high of $291.06 million, reached on December 31, 2020.

Performance

TSHA Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTSHAcash flow metrics

Quarterly CFF:

$8.80M-$207.49M(-95.93%)
September 30, 2025

Summary

  • As of today, TSHA quarterly cash from financing is $8.80 million, with the most recent change of -$207.49 million (-95.93%) on September 30, 2025.
  • Over the past year, TSHA quarterly cash from financing has increased by +$2.20 million (+33.39%).
  • TSHA quarterly cash from financing is now -95.93% below its all-time high of $216.29 million, reached on June 30, 2025.

Performance

TSHA Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTSHAcash flow metrics

TTM CFF:

$224.66M+$2.20M(+0.99%)
September 30, 2025

Summary

  • As of today, TSHA TTM cash from financing is $224.66 million, with the most recent change of +$2.20 million (+0.99%) on September 30, 2025.
  • Over the past year, TSHA TTM cash from financing has increased by +$151.85 million (+208.55%).
  • TSHA TTM cash from financing is now at all-time high.

Performance

TSHA TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTSHAcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

TSHA Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-43.8%+33.4%+208.6%
3Y3 Years+96.2%+8640.8%+1025.0%
5Y5 Years+100.0%--

TSHA Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-43.8%+96.2%-95.9%+307.1%at high+1025.0%
5Y5-Year-73.7%>+9999.0%-95.9%+307.1%at high>+9999.0%
All-TimeAll-Time-73.7%>+9999.0%-95.9%+307.1%at high>+9999.0%

TSHA Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
$8.80M(-95.9%)
$224.66M(+1.0%)
Jun 2025
-
$216.29M(>+9900.0%)
$222.46M(+190.3%)
Mar 2025
-
-$52.00K(+86.1%)
$76.64M(-0.1%)
Dec 2024
$76.68M(-43.8%)
-$375.00K(-105.7%)
$76.68M(+5.3%)
Sep 2024
-
$6.59M(-90.6%)
$72.81M(-64.8%)
Jun 2024
-
$70.47M(>+9900.0%)
$206.85M(+51.3%)
Mar 2024
-
-$4000.00(+99.9%)
$136.76M(+0.3%)
Dec 2023
$136.39M(+161.8%)
-$4.25M(-103.0%)
$136.39M(-25.0%)
Sep 2023
-
$140.63M(>+9900.0%)
$181.87M(+342.1%)
Jun 2023
-
$377.00K(+201.9%)
$41.14M(-20.6%)
Mar 2023
-
-$370.00K(-100.9%)
$51.83M(-0.5%)
DateAnnualQuarterlyTTM
Dec 2022
$52.10M(+33.3%)
$41.23M(>+9900.0%)
$52.10M(+160.9%)
Sep 2022
-
-$103.00K(-100.9%)
$19.97M(-60.1%)
Jun 2022
-
$11.07M(>+9900.0%)
$50.05M(+28.4%)
Mar 2022
-
-$107.00K(-101.2%)
$38.98M(-0.3%)
Dec 2021
$39.08M(-86.6%)
$9.11M(-69.6%)
$39.08M(+37.4%)
Sep 2021
-
$29.98M(>+9900.0%)
$28.44M(+1944.1%)
Jun 2021
-
$0.00(0.0%)
-$1.54M(0.0%)
Mar 2021
-
$0.00(+100.0%)
-$1.54M(-109.4%)
Dec 2020
$291.06M(>+9900.0%)
-
-
Dec 2020
-
-$1.54M(-108.6%)
$16.48M(-8.6%)
Mar 2020
-
$18.03M
$18.03M
Dec 2019
$0.00
-
-

FAQ

  • What is Taysha Gene Therapies, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Taysha Gene Therapies, Inc.?
  • What is Taysha Gene Therapies, Inc. annual cash from financing year-on-year change?
  • What is Taysha Gene Therapies, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Taysha Gene Therapies, Inc.?
  • What is Taysha Gene Therapies, Inc. quarterly cash from financing year-on-year change?
  • What is Taysha Gene Therapies, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Taysha Gene Therapies, Inc.?
  • What is Taysha Gene Therapies, Inc. TTM cash from financing year-on-year change?

What is Taysha Gene Therapies, Inc. annual cash from financing?

The current annual cash from financing of TSHA is $76.68M

What is the all-time high annual cash from financing for Taysha Gene Therapies, Inc.?

Taysha Gene Therapies, Inc. all-time high annual cash from financing is $291.06M

What is Taysha Gene Therapies, Inc. annual cash from financing year-on-year change?

Over the past year, TSHA annual cash from financing has changed by -$59.71M (-43.78%)

What is Taysha Gene Therapies, Inc. quarterly cash from financing?

The current quarterly cash from financing of TSHA is $8.80M

What is the all-time high quarterly cash from financing for Taysha Gene Therapies, Inc.?

Taysha Gene Therapies, Inc. all-time high quarterly cash from financing is $216.29M

What is Taysha Gene Therapies, Inc. quarterly cash from financing year-on-year change?

Over the past year, TSHA quarterly cash from financing has changed by +$2.20M (+33.39%)

What is Taysha Gene Therapies, Inc. TTM cash from financing?

The current TTM cash from financing of TSHA is $224.66M

What is the all-time high TTM cash from financing for Taysha Gene Therapies, Inc.?

Taysha Gene Therapies, Inc. all-time high TTM cash from financing is $224.66M

What is Taysha Gene Therapies, Inc. TTM cash from financing year-on-year change?

Over the past year, TSHA TTM cash from financing has changed by +$151.85M (+208.55%)
On this page